Biodistribution and human dosimetry of enantiomer-1 of the synthetic leucine analog anti-1-amino-2-fluorocyclopentyl-1-carboxylic acid

Nuclear Medicine and Biology

Volumn 38, Issue 7, 2011, Pages 1035-1041

  Nye, Jonathon A ^a   Jarkas, Nashwa ^a   Schuster, David M ^a   Savir Baruch, Bital ^a   Voll, Ronald J ^a   Camp, Vernon M ^a   Goodman, Mark M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amino acid; Anti 2 18F FACPC; Anti 3 18F FACBC; Biodistribution; Dosimetry; FACBC; FACPC; Positron emission tomography

Indexed keywords

1 AMINO 2 FLUOROCYCLOPENTYL 1 CARBOXYLIC ACID F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NONHUMAN; NORMAL HUMAN; PANCREAS; POSITRON EMISSION TOMOGRAPHY; RADIATION ABSORPTION; RADIATION DOSE; SINGLE DRUG DOSE; TOXICITY TESTING; VENOUS BLOOD;

ADULT; ANIMALS; BIOLOGICAL TRANSPORT; CYCLOLEUCINE; FEMALE; HUMANS; LEUCINE; MACACA MULATTA; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOMETRY; STEREOISOMERISM;

EID: 80053612717     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.03.007     Document Type: Article

References (33)

1. Busch H., Davis J.R., Honig G.R., Anderson D.C., Nair P.V., Nyhan W.L. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res 1959, 19:1030-1039.
2. Isselbacher K.J. Sugar and amino acid transport by cells in culture - differences between normal and malignant cells. N Engl J Med 1972, 286(17):929-933.
3. Christensen H.N. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990, 70(1):43-77.
4. Kim S.G., Kim H.H., Kim H.K., et al. Differential Expression and functional characterization of system l amino acid transporters in human normal osteoblast cells and osteogenic sarcoma cells. Anticancer Res 2006, 26(3A):1989-1996.
5. Kobayashi H., Ishii Y., Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 2005, 90(4):233-238.
6. Lin J., Raoof D.A., Thomas D.G., et al. L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 2004, 6(1):74-84.
7. Yanagida O., Kanai Y., Chairoungdua A., et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001, 1514(2):291-302.
8. Nawashiro H., Otani N., Shinomiya N., et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006, 119(3):484-492.
9. Heiss P., Mayer S., Herz M., Wester H.J., Schwaiger M., Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-l-tyrosine in vitro and in vivo. J Nucl Med 1999, 40(8):1367-1373.
10. Wienhard K., Herholz K., Coenen H.H., et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med 1991, 32(7):1338-1346.
11. McConathy J., Goodman M.M. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev 2008, 27(4):555-573.
12. Washburn L.C., Sun T.T., Byrd B., Hayes R.L., Butler T.A. 1-aminocyclobutane[11C]carboxylic acid, a potential tumor-seeking agent. J Nucl Med 1979, 20(10):1055-1061.
13. Shoup T.M., Olson J., Hoffman J.M., et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 1999, 40(2):331-338.
14. Schuster D.M., Votaw J.R., Nieh P.T., et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007, 48(1):56-63.
15. Oka S., Hattori R., Kurosaki F., et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 2007, 48(1):46-55.
16. Jarkas N., Voll R., Camp V., Zhang Z., Goodman M. Characterization of the two enantiomers of anti-18F-FACPC as PET tumor agents. J Nucl Med Meeting Abstracts 2010, 51:1516. 2_MeetingAbstracts.
17. Savir-Baruch B., Schuster D., Jarkas N., et al. Pilot evaluation of 1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma. J Nucl Med Meeting Abstracts 2010, 51:1266. 2_MeetingAbstracts.
18. Jarkas N., Voll R.J., Williams L., Camp V.M., Goodman M.M. (R,S)-Anti-1-amino-2-[18F]fluorocyclopentyl-1-carboxylic acid: synthesis from racemic 2-benzyloxycyclopentanone and biological evaluation for brain tumor imaging with positron emission tomography. J Med Chem 2010, 53(18):6603-6607.
19. McConathy J., Voll R.J., Yu W., Crowe R.J., Goodman M.M. Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot 2003, 58(6):657-666.
20. Yu W., McConathy J., Williams L., et al. Synthesis, radiolabeling, and biological evaluation of (R)- and (S)-2-amino-3-[(18)F]fluoro-2-methylpropanoic acid (FAMP) and (R)- and (S)-3-[(18)F]fluoro-2-methyl-2-N-(methylamino)propanoic acid (NMeFAMP) as potential PET radioligands for imaging brain tumors. J Med Chem 2010, 53(2):876-886.
21. Mawlawi O., Podoloff D.A., Kohlmyer S., et al. Performance characteristics of a newly developed PET/CT scanner using NEMA standards in 2D and 3D modes. J Nucl Med 2004, 45(10):1734-1742.
22. ICRP Radiation dose to patients from radiopharmaceuticals. Publication 53. Vol 18/1-4 1988.
23. Stabin M.G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996, 37(3):538-546.
24. Yu W., Williams L., Camp V.M., Malveaux E., Olson J.J., Goodman M.M. Stereoselective synthesis and biological evaluation of syn-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid as a potential positron emission tomography brain tumor imaging agent. Bioorg Med Chem 2009, 17(5):1982-1990.
25. Martarello L., McConathy J., Camp V.M., et al. Synthesis of syn- and anti-1-amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic acid (FMACBC), potential pet ligands for tumor detection. J Med Chem 2002, 45(11):2250-2259.
26. Wester H.J., Herz M., Weber W., et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumor imaging. J Nucl Med 1999, 40(1):205-212.
27. Pauleit D., Floeth F., Herzog H., et al. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-l-tyrosine. Eur J Nucl Med Mol Imaging 2003, 30(4):519-524.
28. Fujibayashi Y., Kawai K., Yonekura Y., Matsumoto K., Konishi J., Yokoyama A. Problems of [S-methyl-11C]-l-methionine as a protein synthesis marker in the pancreas. Ann Nucl Med 1990, 4(1):29-33.
29. Deloar H.M., Fujiwara T., Nakamura T., et al. Estimation of internal absorbed dose of l-[methyl-11C]methionine using whole-body positron emission tomography. Eur J Nucl Med 1998, 25(6):629-633.
30. Nye J.A., Schuster D.M., Yu W., Camp V.M., Goodman M.M., Votaw J.R. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med 2007, 48(6):1017-1020.
31. Börner A.R., Langen K.J., Herzog H., et al. Whole-body kinetics and dosimetry of cis-4-[18F]fluoro-l-proline. Nucl Med Biol 2001, 28(3):287-292.
32. Savir-Baruch B, Schuster DM, Jarkas N, et al. Pilot Evaluation of anti-1-amino-2-[18F]fluorocyclopentane-1-carboxylic acid (anti-2-[18F]FACPC) PET-CT in recurrent prostate carcinoma. Molecular Imaging and Biology. in press.
33. Charles M.W. ICRP publication 103: recommendations of the ICRP†. Radiat Prot Dosimetry 2008, 129(4):500-507.